Supported by the Office of International Affairs, National Cancer Institute (NCI), the" US-
Japan Workshop on Immunological Biomarkers in Oncology" was held in March 2009. The …

Abstract The International Society for the Biological Therapy of Cancer (iSBTc) has initiated
in collaboration with the United States Food and Drug Administration (FDA) a programmatic …

Abstract The International Society for Biological Therapy of Cancer (iSBTc, recently renamed
the Society for Immunotherapy of Cancer, SITC) hosted a one-day symposium at the …

The recent successes in the use of immunotherapy to treat cancer have led to a multiplicity
of new compounds in development. Novel clinical-grade biomarkers are needed to guide …

The rapid expansion of modern cancer immunotherapeutics has led to a dramatic
improvement in patient survival and sustained remission for otherwise refractory …

This book provides the immune oncology (IO) community with a deeper understanding of the
scope of the biomarker methods to potentially improve the outcome from immunotherapy …

Immunotherapies have emerged as one of the most promising approaches to treat patients
with cancer. Recently, there have been many clinical successes using checkpoint receptor …

This report summarizes the symposium,'Immunotherapy Biomarkers 2016: Overcoming the
Barriers', which was held on April 1, 2016 at the National Institutes of Health in Bethesda …

There is growing recognition that immunotherapy is likely to significantly improve health
outcomes for cancer patients in the coming years. Currently, while a subset of patients …

The revolution of immunotherapies in oncology has not been matched by the development
of companion diagnostic biomarkers able to identify the ideal target populations. Aside from …